ledipasvir
Jump to navigation
Jump to search
Indications
- used in combination with sofosbuvir in an experimental treatment of hepatitis C infection (genotype 1)
Mechanism of action
- antiviral protease inhibitor, inhibits NS5A
More general terms
Component of
References
- ↑ Lawitz E et al Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet, Early Online Publication, 5 November 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24209977 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62121-2/abstract